Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 16.51 0.01 (0.06%) Market Cap: 1.41 Bil Enterprise Value: 1.00 Bil PE Ratio: 0 PB Ratio: 3.84 GF Score: 43/100

Q4 2022 Syndax Pharmaceuticals Inc Earnings Call Transcript

Feb 28, 2023 / 09:30PM GMT
Release Date Price: $25.35 (+3.60%)
Operator

Good day, everyone, and welcome to the Syndax Fourth Quarter 2022 Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.

Sharon Klahre
Syndax Pharmaceuticals, Inc. - VP of IR & Communications

Thank you, operator. Welcome, and thank you all for joining us today for the review of Syndax's fourth quarter and full year 2022 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and to discuss financial results are: Michael Metzger, Chief Executive Officer; Dr. Briggs Morrison, President and Head of R&D; and Keith Goldan, Chief Financial Officer. Also joining us on the call today for question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; Dr. Anjali Ganguli, Chief Business Officer.

This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. We can now turn to our forward-looking statements on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot